Menu
Recruiting NCT04330599

Longitudinal Population-based Observational Study of COVID-19 in the UK Population

— Observational COVID-19

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: COVID-19. Basic parameters: from 16 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United Kingdom
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

COVIDENCE UK is a population-based observational longitudinal study that has the following objectives: 1. To determine risk factors for incident COVID-19 and for adverse outcomes of COVID-19 in the UK population 2. To characterise the natural history of COVID-19 in the UK population 3. To evaluate the impact of COVID-19 on the physical and mental health of the UK population 4. To provide a resource from which to identify potential participants for future clinical trials, and to use data collected in COVIDENCE as comparison or control data for trial participants who have been randomised to receive one or more interventions.

Primary outcome measures

  • Incidence of confirmed COVID-19 [Time frame: 5 years]
Secondary outcome measures (12)
  • Incidence of probable or suspected COVID-19 [Time frame: 5 years]
  • Incidence of COVID-19 requiring hospitalisation [Time frame: 5 years]
  • Incidence of COVID-19 requiring ventilatory support [Time frame: 5 years]
  • Incidence of fatal COVID-19 [Time frame: 5 years]
  • Symptom duration per COVID-19 episode [Time frame: 5 years]
  • Symptom severity per COVID-19 episode [Time frame: 5 years]
  • Incidence of seroconversion to SARS-CoV-2 [Time frame: 5 years]
  • Incidence of recurrent COVID-19 [Time frame: 5 years]
  • EQ-5D-3L health-related quality of life score [Time frame: 5 years]
  • Health care costs associated with incident COVID-19 [Time frame: 5 years]
  • Impact of the COVID-19 pandemic and the societal response on participants' financial status [Time frame: 5 years]
  • Incidence of COVID-19 on participant's physical health [Time frame: 5 years]

Eligibility criteria

Inclusion criteria

  • UK resident
  • Age ≥16 years

Exclusion Criteria: none

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Cohort

Study locations

United Kingdom · 1 center
  • Queen Mary University of London — London

Publications

  • Vivaldi G, Talaei M, Blaikley J, Jackson C, Pfeffer PE, Shaheen SO, Martineau AR. Bidirectional relationship between sleep problems and long COVID: a longitudinal analysis of data from the COVIDENCE UK study. BMJ Open Respir Res. 2025 Jun 15;12(1):e002506. doi: 10.1136/bmjresp-2024-002506. PMID 40518292
  • Vivaldi G, Pfeffer PE, Talaei M, Basera TJ, Shaheen SO, Martineau AR. Long-term symptom profiles after COVID-19 vs other acute respiratory infections: an analysis of data from the COVIDENCE UK study. EClinicalMedicine. 2023 Oct 6;65:102251. doi: 10.1016/j.eclinm.2023.102251. eCollection 2023 Nov. PMID 38106559
  • Tydeman F, Pfeffer PE, Vivaldi G, Holt H, Talaei M, Jolliffe D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Shaheen SO, Martineau AR. Rebound in asthma exacerbations following relaxation of COVID-19 restrictions: a longitudinal population-based study (COVIDENCE UK). Thorax. 2023 Aug;78(8):752-759. doi: 10.1136/thorax-2022-219591. Epub 2022 Nov 23. PMID 36423925
  • Williamson AE, Tydeman F, Miners A, Pyper K, Martineau AR. Short-term and long-term impacts of COVID-19 on economic vulnerability: a population-based longitudinal study (COVIDENCE UK). BMJ Open. 2022 Aug 23;12(8):e065083. doi: 10.1136/bmjopen-2022-065083. PMID 35998959
  • Holt H, Talaei M, Greenig M, Zenner D, Symons J, Relton C, Young KS, Davies MR, Thompson KN, Ashman J, Rajpoot SS, Kayyale AA, El Rifai S, Lloyd PJ, Jolliffe D, Timmis O, Finer S, Iliodromiti S, Miners A, Hopkinson NS, Alam B, Lloyd-Jones G, Dietrich T, Chapple I, Pfeffer PE, McCoy D, Davies G, Lyons RA, Griffiths C, Kee F, Sheikh A, Breen G, Shaheen SO, Martineau AR. Risk factors for developing C PMID 34848555

Identifiers

NCT: NCT04330599 · COVIDENCE UK

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗